Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safety in numbers--monitoring risk in approved drugs.

Literature DB >> 15788493

Safety in numbers--monitoring risk in approved drugs.

Susan Okie.

Abstract

Mesh：

Year: 2005 PMID： 15788493 DOI： 10.1056/NEJMp058029

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

Review 1. Assessing long-term drug safety: lessons (re) learned from raptiva.

Authors: Nicole M Seminara; Joel M Gelfand
Journal: Semin Cutan Med Surg Date: 2010-03

2. Fixing flaws in Medicare drug coverage that prompt insurers to avoid low-income patients.

Authors: John Hsu; Vicki Fung; Jie Huang; Mary Price; Richard Brand; Rita Hui; Bruce Fireman; William H Dow; John Bertko; Joseph P Newhouse
Journal: Health Aff (Millwood) Date: 2010-10-28 Impact factor: 6.301

Review 3. Medical paternalism and expensive unsubsidised drugs.

Authors: Michael Jefford; Julian Savulescu; Jacqui Thomson; Penelope Schofield; Linda Mileshkin; Emilia Agalianos; John Zalcberg
Journal: BMJ Date: 2005-11-05

4. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.

Authors: Harald E Heemstra; Thijs J Giezen; Aukje K Mantel-Teeuwisse; Remco L A de Vrueh; Hubert G M Leufkens
Journal: Drug Saf Date: 2010-02-01 Impact factor: 5.606

Review 5. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Authors: Erica D Dommasch; Katrina Abuabara; Daniel B Shin; Josephine Nguyen; Andrea B Troxel; Joel M Gelfand
Journal: J Am Acad Dermatol Date: 2011-02-18 Impact factor: 11.527

Safety in numbers--monitoring risk in approved drugs.

Review 1. Assessing long-term drug safety: lessons (re) learned from raptiva.

2. Fixing flaws in Medicare drug coverage that prompt insurers to avoid low-income patients.

Review 3. Medical paternalism and expensive unsubsidised drugs.

4. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.

Review 5. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Review 6. Integration of PKPD relationships into benefit-risk analysis.

7. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso.

8. Evaluation of drug toxicity in clinical trials.

Review 9. Causality assessment in hepatotoxicity by drugs and dietary supplements.

10. Beyond post-marketing research and MedWatch: Long-term studies of drug risks.